Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 11Sarcoma 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Inflammatory Breast Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER-2 Positive Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inoperable Locally Advanced HER2-Negative Breast Cancer × eribulin × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡